MARTINSRIED/PLANEGG GERMANY - MorphoSys AG announced in a press release that the European Patent Office has granted a European divisional patent stemming from MorphoSys's base HuCAL (Human Combinatorial Antibody Library) patent family, providing extended protection for the company's core technology.
The new patent (EP1143006) captures HuCAL's modular design at the DNA level, providing solid product claim protection in Europe.
MorphoSys's HuCAL libraries comprise highly diverse, fully human synthetic antibodies that are highly engineerable through their modular CDR design.
Its most advanced marketed version, HuCAL PLATINUM, provides rapid access to fully human antibodies as research tools, diagnostics and therapeutics. A first European HuCAL patent, which is now complemented by the new patent, was issued by the European Patent Office in 2002.
"This new patent is a further example of the pioneering nature of our proprietary core technology, HuCAL, and provides us with another solid layer of protection in Europe,” MorphoSys AG CEO Dr. Simon Moroney commented.
“We will carry on with this process, continuing to build a strong Intellectual Property portfolio around HuCAL and our other antibody-related technologies," he added.
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases.
